MAPK3 and neoplasm: In the present study, we report that apoEdp inhibits VEGF-mediated receptor (VEGFR2/Flk-1) activation and downstream signaling (c-Src, FAK, Akt, eNOS, Erk1/2) pathways of angiogenesis pertinent to tumor development and progression.